2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non–small cell small cancer (NSCLC).
Brandon Weckbaugh, MD, an oncology fellow at the University of Missouri-Kansas City, discusses the results of the LIBRETTO-001 trial in the patients with non—small cell small cancer (NSCLC).
The LIBRETTO-001 trial (NCT03157128) is a phase I/II trial investigating LOXO-292 in patients with advanced solid tumors, RET fusion—positive solid tumors, and medullary thyroid cancer. LOXO-292 is a TKI targeting the RET mutation. Data from the trial showed some encouraging responses in patients with RET fusion mutation-driven cancers, irrespective of the RET fusion partner, as well as prior kinase inhibitor therapy, says Weckbaugh.
In September 2018, the FDA granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion—positive NSCLC or RET-mutant medullary thyroid cancer. The breakthrough therapy designation is specific to patients with metastatic RET fusion-positive NSCLC who require systemic therapy and have progressed following platinum-based chemotherapy and an anti—PD-1 or anti–PD-L1 therapy.